<DOC>
	<DOCNO>NCT00505037</DOCNO>
	<brief_summary>To evaluate superiority placebo , dose-responsibility safety .</brief_summary>
	<brief_title>A Phase 2 Study ASP1585 Chronic Kidney Disease Patients With Hyperphosphatemia Hemodialysis</brief_title>
	<detailed_description>This multi-center , randomize , double blind placebo-controlled open label sevelamer hydrochloride-controlled , dose-ranging study CKD patient hyperphosphatemia hemodialysis . Patients randomly allocate one five treatment group ( ASP1585 : 3 dose , placebo , Sevelamer hydrochloride ) advance 4-week treatment period .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Hyperphosphatemia</mesh_term>
	<mesh_term>Sevelamer</mesh_term>
	<criteria>Stable CKD patient currently hemodialysis three time week least 12 week prior acquisition inform consent Patients stable dose ( ) phosphate binder ( ) least 28 day prior acquisition inform consent . Patients stable dose ( ) Vitamin D calcitonin agent least 28 day prior acquisition inform consent , case patient treat agent History major gastrointestinal surgery , swallow disorder , bowel obstruction , hemorrhagic gastrointestinal lesion Continuous severe constipation/diarrhea . History parathyroid intervention [ parathyroidectomy（PTx），percutaneous ethanol injection therapy（PEIT）etc . ] within 1 year acquisition inform consent Diet restriction fast and/or excessive dieting Uncontrolled hypertension</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>ASP1585</keyword>
	<keyword>Renal Dialysis</keyword>
	<keyword>Chronic Kidney Disease</keyword>
	<keyword>Hyperphosphatemia</keyword>
</DOC>